Propel Bio Management LLC Has $2.42 Million Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Propel Bio Management LLC lifted its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 37.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 183,259 shares of the company's stock after acquiring an additional 50,000 shares during the period. Syndax Pharmaceuticals makes up 2.4% of Propel Bio Management LLC's portfolio, making the stock its 11th largest holding. Propel Bio Management LLC owned approximately 0.21% of Syndax Pharmaceuticals worth $2,423,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Virtus ETF Advisers LLC lifted its position in Syndax Pharmaceuticals by 18.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after purchasing an additional 827 shares during the period. Nebula Research & Development LLC lifted its position in Syndax Pharmaceuticals by 325.6% in the fourth quarter. Nebula Research & Development LLC now owns 76,914 shares of the company's stock worth $1,017,000 after purchasing an additional 58,844 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Syndax Pharmaceuticals by 16.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 57,019 shares of the company's stock worth $754,000 after purchasing an additional 8,092 shares during the period. Hsbc Holdings PLC lifted its position in Syndax Pharmaceuticals by 15.3% in the fourth quarter. Hsbc Holdings PLC now owns 50,747 shares of the company's stock worth $656,000 after purchasing an additional 6,741 shares during the period. Finally, Stifel Financial Corp lifted its position in Syndax Pharmaceuticals by 120.8% in the fourth quarter. Stifel Financial Corp now owns 37,475 shares of the company's stock worth $495,000 after purchasing an additional 20,499 shares during the period.

Syndax Pharmaceuticals Trading Up 2.1 %

Shares of SNDX traded up $0.28 during mid-day trading on Tuesday, hitting $13.70. 1,658,920 shares of the company traded hands, compared to its average volume of 1,599,501. The business has a 50-day moving average of $13.05 and a 200 day moving average of $14.81. Syndax Pharmaceuticals, Inc. has a one year low of $9.66 and a one year high of $25.07. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -3.77 and a beta of 1.28.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The company had revenue of $7.68 million for the quarter, compared to analyst estimates of $86.32 million. As a group, analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on SNDX shares. Citigroup cut their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Scotiabank reduced their price target on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research report on Wednesday, January 8th. JPMorgan Chase & Co. upped their price objective on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Finally, StockNews.com raised shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $36.20.

Insider Activity at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,777 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the sale, the chief financial officer now directly owns 90,746 shares in the company, valued at approximately $1,406,563. This trade represents a 4.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the sale, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,683 shares of company stock worth $336,087 over the last ninety days. Company insiders own 4.10% of the company's stock.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).